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Abstract
Background: Globally, 1 in 11 adults has diabetes mellitus, 
and most of these cases are type 2 diabetes (T2D). The risk of 
T2D is influenced by many factors, including diet. The syn-
thesis of long-chain n-6 polyunsaturated fatty acids (LC n-6 
PUFA) has been posited as a risk factor for T2D; however, its 
causal role is uncertain. Aim: To test the causal effect of LC 
n-6 PUFA synthesis on insulin resistance and transgenera-
tional T2D risk in a large cohort of men and women. Meth-
ods: Two-sample mendelian randomization (MR) was con-
ducted to evaluate the effect of low or high levels of LC n-6 
PUFA synthesis on glycemia and development of T2D in the 
UK Biobank (n = 463,010) and Meta-Analysis of Glucose- and 
Insulin-Related Traits Consortium (MAGIC; n = 5,130) co-
horts. The increased likelihood of a predisposition to low or 
high LC n-6 PUFA synthesis and the risk of T2D was also in-
vestigated using the participants’ siblings and parents. In 
MR-Base, 4 genetic variants associated with LC n-6 PUFA syn-
thesis were found (p < 10–8). After pruning, 1 variant 
(rs174547) on the FADS1 gene was retained. Results: Lower 
LC n-6 PUFA synthesis and abundance (per % unit decrease) 
are associated with small reductions in the insulin disposi-
tion index (–0.038 ± 0.012 mM–1; p = 0.002) within MAGIC. In 
the UK Biobank, we report negligible effects of low n-6 PUFA 
synthesis on the odds of T2D (OR < 1%; p < 0.05). Addition-
ally, reduced LC n-6 PUFA synthesis does not appear to be a 
contributor to familial T2D risk. No significant association 
was observed between LC n-6 PUFA synthesis and BMI. Con-
clusion: In a primarily white European population, LC n-6 
PUFA synthesis is not a major contributor to T2D risk.
© 2020 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Globally, nearly 1 in 11 adults are diabetic, and 90% of 
them have type 2 diabetes (T2D). T2D is characterized by 
a deterioration of β-cell function, often preceded by insu-
lin resistance [1]. A number of mechanisms underlying 
β-cell dysfunction have been proposed, including genet-
ics, bodyweight and adiposity, smoking, inflammation, 
physical activity, and diet [2–5].
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Dietary fats have been positioned as an important risk 
factor for T2D, with polyunsaturated fatty acids (PUFA) 
demonstrating a strong association with glucose metabo-
lism [6]. A meta-analysis of 102 clinical trials (n = 4,220 
adults) reported that isocaloric replacement of carbohy-
drates with PUFA improved glycemia levels (–0.11 
HbA1c %; 95% CI –0.17 to –0.05; –1.6 pmol/L fasting in-
sulin; 95% CI –2.8 to –0.4) and insulin secretion (+0.5 
pmol/L/min; 95% CI 0.2 to 0.8) more significantly than 
replacement with saturated (SFA) or monounsaturated 
(MUFA) [6] Observational studies have reported similar 
results and estimated that a low dietary PUFA consump-
tion may be responsible for up to 20% (population-attrib-
utable fraction) of T2D cases [7]. However, heterogeneity 
between studies, insufficient power, and confounding [8–
10] limit our interpretation of these results.
Of particular interest is the rate of synthesis and abun-
dance of long-chain n-6 PUFA (LC n-6 PUFA), i.e., ara-
chidonic acid (ARA; 20: 4 n-6), from shorter precursor 
n-6 PUFA such as linoleic acid (LA; 18: 2 n-6) (Fig. 1). 
Although the specific mechanisms remain elusive, it has 
been observed that exposure of primary β-cell cultures to 
elevated levels of ARA by (1) exogenous application or (2) 
impeding the conversion of ARA to eicosanoids stimu-
lates insulin secretion from human islets [11, 12], sug-
gesting that the metabolism and abundance of LC n-6 
PUFA has a direct effect on insulin secretion. Moreover, 
a nested case-control study (n = 2,787, with 673 cases of 
T2D) within the European Prospective Investigation into 
Cancer and Nutrition (EPIC)-Potsdam cohort reported 
that higher rates of ARA synthesis resulted in a 54% re-
duction in the risk of T2D (RR = 0.46; 95% CI 0.31–0.70; 
p-trend < 0.0001), compared to the lowest quintile, in 
their fully adjusted model [13]. Collectively, this suggests 
that LC n-6 PUFA are associated with the risk of T2D and 
may be driven by ARA acting on β-cell insulin secretion; 
however, such studies are limited by confounding. Con-
founding is the uncertainty introduced by inaccurate or 
unaccounted variables (e.g., cooking method) [14, 15] 
that are linked to both the exposure (i.e., ARA) and the 
outcome (i.e., β-cell insulin secretion) [16].
To overcome the effects of confounding and provide 
evidence of a causal association, EPIC elected to use a 
mendelian randomization (MR) approach. Briefly, MR 
uses genetic variants associated with exposure as surro-
gate measures of that exposure (i.e., instrumental vari-
ables). The use of genetic variants (e.g., single-nucleotide 
polymorphisms; SNP) permits the inference of causality 
between these exposures and the outcome because genet-
ic variants are (1) randomly assorted at meiotic segrega-
tion and (2) assigned at conception. In a way, this model 
resembles a life-long randomized controlled trial where 
the exposures and confounders (e.g., fish intake, fish oil 
supplementation, physical activity, and household in-
come) are also randomly distributed [16, 17]. The aim 
was for the MR analysis undertaken by the EPIC study to 
demonstrate a causally protective effect of ARA on T2D 
[13]. However, the wide confidence intervals (RR = 0.98; 
95% CI 0.70–1.37) they attained suggested that, if an as-
sociation exists, a larger sample would be needed to re-
flect the true causal association between n-6 PUFA syn-
thesis and T2D. Two-sample MR [18] harnesses summa-
ry association results from nonoverlapping groups of 
individuals to estimate novel causal effects. This method 
increases the utility of large cohorts for MR studies be-
cause researchers are not reliant on a single cohort to pro-
vide exposure and outcome data; in 2-sample MR any 2 
independent cohorts may be used ‒ one to summarize the 
genetic variant-exposure association and another to sum-
marize the genetic variant-outcome association. With 
this methodology and access to large cohorts with suit-




















Fig. 1. n-6 and n-3 PUFA synthesis. LC n-6 and n-3 PUFA can be 
synthesized from precursor PUFA (LA or ALA) by alternating re-
actions of desaturation and elongation. Desaturation is driven by 
δ-6 and δ-5 desaturase (D5D and D6D), coded by fatty acid de-
saturase (FADS1 or FADS2), while elongation is driven by elon-
gase, coded by elongation 2 or 5 (ELOVL 2 or ELOVL 5). 
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To build on previous evidence, we propose the use of 
2-sample MR to assess the causal association between LC 
n-6 PUFA synthesis and the risk of T2D.
Methods
Instrumental Variables
We performed 2-sample MR using MR-Base [19] with sum-
mary data from publicly available GWAS databases (online suppl. 
Fig. 1; see www.karger.com/doi/10.1159/000509663 for all online 
suppl. material).
Sample 1
With MR-Base [19], instrumental variables (SNP) associated 
(p < 5 × 10−8) with plasma levels (% total fatty acids) of ARA were 
identified. From the Cohorts for Heart and Aging Research in Ge-
nomic Epidemiology Consortium (CHARGE; n = 8,631 white Eu-
ropeans; 55% women) [20] ‒ comprising the Atherosclerosis Risk 
in Communities (ARIC), Coronary Artery Risk Development in 
Young Adults (CARDIA), Cardiovascular Health Study (CHS), 
Invecchiare in Chianti (InCHIANTI), and Multi-Ethnic Study of 
Atherosclerosis (MESA) ‒ the following 4 SNP were identified: 
rs174547, rs102275, rs1741, and rs16829840. From a nested case-
control study of myocardial infarction within the Singapore Chi-
nese Health Study (SCHS; n = 1,540) the following 2 SNP were 
identified: rs174577 and rs174548. Of the 6 SNP identified, the 
following 2 were removed because their biological function and 
mechanism of association with ARA were unknown, which risks 
violation of MR (i.e., no horizontal pleiotropy between SNP and 
outcome): rs1741, a non-coding intron variant strongly associated 
with vitamin B6-dependent decarboxylase (it is unknown whether 
this variant alters carboxylase expression); and rs16829840, a non-
coding transcript variant of transmembrane protein (TMEM39A) 
with an uncertain function and cellular location [21]. Therefore, 
only 4 SNP (rs174547, rs102275, rs174577, and rs174548) pro-
gressed and were evaluated for inclusion in 2-sample MR.
Sample 2
Using previously published data within MR-Base, summary as-
sociations for each of the 4 SNP were obtained for: (1) insulin dis-
position index (DI) in the Meta-Analysis of Glucose- and Insulin-
Related Traits Consortium (MAGIC; white European men and 
women; n = 5,130) and (2) self-reported diagnosis of T2D in the 
UK Biobank (95% white European men and women, n = 463,010). 
The DI, calculated following an oral glucose tolerance test, is as-
sociated with beta-cell function (p < 0.001) and is a predictor of 
future T2D (Area Under the Curve = 0.86; 95% CI: 0.82, 0.89) [22], 
whereby a lower or reduction in a person’s DI is associated with a 
shift from normal glucose tolerance to impaired glucose metabo-
lism and an increased risk of T2D. 
In case an SNP was not present in MAGIC or the UK Biobank, 
a proxy SNP in high linkage disequilibrium (r2 ≥ 0.80) would be 
identified; however, proxy SNP were not required as all SNP were 
in both databases. Palindromic SNP were permitted with a minor 
allele frequency threshold of 0.30 to allow for a high degree of con-
fidence that sample 1 and sample 2 datasets were coded in the same 
direction [23]. SNP were tested for independence and clumped 
(r2 < 0.001). Using MR-Base and the ld_matrix function (TwoSam-
pleMR) in R (v.3.5.1), we observed LD with R2 > 0.92 between SNP 
within the 1000 Genomes Project of European samples. As depict-
ed in Figure 1, the genes/enzymes for elongation and desaturation 
are shared by the n-6 and n-3 pathways; therefore, a single SNP 
may be associated with multiple PUFA. To negotiate this link, we 
used existing summary data [20] to confirm that our instrumental 
variable (rs174547) explained a very high degree of variation of n-6 
PUFA levels and, comparatively, little variation of n-3 PUFA levels. 
While the effect of rs174547 is significant across numerous PUFA, 
the magnitude of the effect of rs174547 on n-6 PUFAs is signifi-
cantly greater (up to 22-fold more) [24], suggesting that rs174547 
is primarily a regulator of n-6 PUFA synthesis. Underlying this as-
sociation is the large pool of LA, a short chain n-6 PUFA, which 
constitutes ≈90% of all dietary PUFA and precursor of endoge-
nously synthesized long-chain n-6 PUFA [25]. Furthermore, as 
shown in Table 1, we see that while rs174547 may not be an ideal 
instrumental variable for a single n-6 PUFA, that it is most strong-
ly associated with n-6 PUFAs at opposite ends of the pathway and 
in opposite directions – i.e., higher levels of LA (an essential short-
chain n-6 PUFA; β = +1.47 [0.05] % total fatty acids, p = 5.0 × 
10−274) and lower levels of arachidonic acid (a major LC n-6 PUFA 
and precursor of eicosanoids; β = −1.69 [0.02] % total fatty acids, 
p = 3.0 × 10−971). Therefore, we used rs174547 as an instrumental 
variable of n-6 PUFA synthesis and report all MR associations per 
1% unit decrease in arachidonic acid of total plasma fatty acids (i.e., 
lower n-6 PUFA synthesis). This genetic variant demonstrates no 
association with common confounders of diabetes, such as self-
reported “smoking” or “alcohol intake” in the UK Biobank [26]. In 
summary, rs174547 meets the 3 assumptions of MR [27], i.e.: 
(1) correlated with the study exposure (n-6 PUFA synthesis); 
Table 1. Association between the SNP and the instrumental variable (rs174547) and n-6 polyunsaturated fatty 
acids (PUFAs)
n-6 PUFA β SE p value R2 (%)
Linoleic acid (LA) 1.47 0.05 5.00E–274 7.6–18.1
γ-Linoleic acid (GLA) –0.016 0.001 2.30E–72 2.2–4.6
Di-homo-γ-linoleic acid (DGLA) 0.36 0.01 2.60E–151 8.7–11.1
Arachidonic acid (ARA) –1.69 0.02 3E–971 3.7–37.6
The SNP rs174547 (C/T) has a signifciant effect on n-6 PUFA levels, with an effect allele (C) frequency of 0.33.
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(2) presents no association with other confounding factors (i.e., 
smoking and alcohol), and (3) offers no alternative independent 
biological pathway to modify the outcome (i.e., only via n-6 PUFA 
synthesis).
Within the UK Biobank, we also performed an exploratory anal-
ysis of family history of T2D. Briefly, given that at least one parent of 
any individual carrying the risk allele (T) of the rs174547 SNP must 
also carry the same risk allele, it can be expected that the effect of the 
SNP on n-6 PUFA synthesis and T2D risk must also be observed in 
at least one parent. Further, we expect siblings of a participant that 
carry the rs174547 risk allele to also be more likely to carry this allele 
and present an association between n-6 PUFA and T2D risk. Data 
distinguishing between full and half siblings was not available.
Finally, to test whether an association between n-6 PUFA syn-
thesis and T2D is mediated by changes in adiposity, we also investi-
gated whether n-6 PUFA synthesis was causally associated with BMI 
in men and women within the GIANT consortium (n = 322,154).
Statistical Methods
Gathering our exposure (sample 1) and outcome (sample 2) 
summary results was the first step towards calculating 2-sample 
MR estimates of n-6 PUFA synthesis on dysglycemia or the odds 
of T2D. In the present study, the online tool mRnd (http://cnsge-
nomics.com/shiny/mRnd/) [28] estimated the study power to be 
over 90% and an F statistic > 11 to detect a significant difference 
(p < 0.05) in the risk of T2D of 5%, assuming a conservative mean 
r2 of 0.20 between our instrumental variable and exposure and a 
proportion of T2D in the UK Biobank of at least 5% [29].
With a genetic instrument comprised of 1 SNP, the estimator 
for assessing a causal association between reduced n-6 PUFA syn-
thesis and dysglycemia or T2D is the Wald estimate [30] (Fig. 2). 
This procedure relies on a relatively simple mathematical equation 
to calculate the causal effect of the exposure on the outcome. In 
line with the assumptions of MR, the effect of βGE (i.e., the differ-
ence in n-6 PUFA synthesis due to genetics/SNP) and βEO (the ef-
fect of genetically-mediated n-6 PUFA synthesis on dysglycemia 
or T2D) are essentially free of confounding (due to random assort-
ment of alleles at meiosis and conception) and horizontal pleiot-
ropy. Therefore, βGO (the direct effect of the SNP on dysglycemia 
or T2D) is simply the product of βGE and βEO (βGO = βGE × βEO). 
Having already collected the estimates of βGE and βGO from the 
summary data above, the equation can be rearranged to solve for 
βEO, our primary research question, the causal association between 
n-6 PUFA synthesis and dysglycemia or T2D. Results were calcu-
lated per SD change in ARA but converted to percent unit change 
(i.e., 1%) for easier interpretation.
Results
MR results are shown in Table 2. Firstly, in the MAG-
IC cohort, we report a small but significant association 
between a 1% reduction of n-6 PUFA synthesis and the 
insulin DI (–0.038 mM–1; p = 0.002). Secondly, within the 
UK Biobank, we report very small but significant associa-
tions between a 1% reduction of n-6 PUFA synthesis and 
the odds of T2D in participants (OR = 1.001; 95% CI 
Table 2. Causal association estimates of the effect of reduced n-6 PUFA synthesis on dysglycemia and the risk of type 2 diabetes
Outcome Wald estimate
β SE p value n OR (95% CI)
Insulin Disposition Index (mM–1) –0.038 0.012 0.002 5,318
Participant T2D 0.0005 0.0003 0.049 461,578 1.001 (1.000–1.001)
Mother T2D 0.0008 0.0004 0.042 423,892 1.001 (1.000–1.002)
Father T2D 0.0008 0.0004 0.054 400,687 1.001 (1.000–1.002)
Sibling T2D 0.0005 0.0004 0.238 362,826 1.000 (1.000–1.001)
Body mass index (kg/m2) –0.0015 0.0020 0.449 322,154
There is a causal association of a 1% reduction of n-6 PUFA synthesis (i.e., a 1% reduction of ARA abundance) on Participant Dis-
position Index (mM–1) and the risk of participant, parent, or sibling of type 2 diabetes (T2D). Diagnoses of T2D were self-reported by 
the primary particpant. SE, standard error.







Fig. 2. Wald estimate. The vertices of the triangle represent: G, ge-
netic variants (SNP) associated with our exposure and outcome; E, 
exposure of interest; and O, outcome of interest. As such, the sides 
of the triangle represent: βGE, the association between specific SNP 
and the exposure; βGO, the association between specific SNP and 
the outcome; and βEO, the association between the exposure and 
the outcome. The Wald ratio states that if βGE and βEO are free of 
confounding, then their product is equal to βGO. Therefore, by re-
arranging this equation, βEO, the unconfounded association be-
tween n-6 PUFA and dysglycemia and T2D can be investigated.
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1.000–1.001; p = 0.049). Thirdly, in or exploratory analy-
sis of familial risk of T2D, we report that mothers of indi-
viduals with reduced n-6 PUFA synthesis are only more 
likely to have had T2D by the smallest of margins (OR = 
1.001; 95% CI 1.000–1.002; p = 0.042), but not their fa-
thers or siblings. 
In our previous work, we observed reductions of n-6 
PUFA synthesis of ∼1.7% following a 3-month supple-
mentation of fish oils (2 g eicosapentaenoic acid and 1 g 
docosahexaenoic acid) in young and older men [31]. 
Therefore, we also present estimates of effect sizes which 
are proportional to a 1.7% reduction of n-6 PUFA synthe-
sis. For DI, this equates to a reduction of –0.0665 (0.021) 
mM–1. Put into context, where an increase of 1 unit of DI 
is associated with a 60% lower odds of developing T2D 
within 10 years (OR = 0.40; 95% CI 0.25–0.66; p < 0.001) 
[22], a reduction –0.0665 mM–1 is associated with a 6% in-
creased risk of T2D within 10 years. For diagnosis of T2D, 
the difference in effect size between a 1% (log OR1% = 
0.0005) and a 1.7% reduction in n-6 PUFA synthesis is 
negligible (log OR1.7% = 0.00095). Put into perspective, 
within the UK Biobank where a high proportion of habit-
ual fish oil intake was reported (31.2%) [32], we estimate 
that fewer than 0.03% of cases of T2D may be attributed to 
fish oil supplementation (population attributable risk).
Finally, our MR model did not report a significant as-
sociation between n-6 PUFA synthesis and BMI (p = 
0.449) within the GIANT consortium.
Discussion
Using a 2-sample MR approach, we report that a re-
duction of n-6 PUFA synthesis is associated with T2D 
risk, but its effect is trivial. Additionally, we report that 
n-6 PUFA synthesis is not a major contributor to a fam-
ily history of T2D.
With the relatively recent application of MR, the ma-
jority of analyses investigating the association between 
n-6 PUFA synthesis (or ARA abundance) and risk of T2D 
has been undertaken in large cohorts. Most recently, the 
Multi-Ethnic Study of Atherosclerosis (MESA) cohort (n 
= 6,282) reported an inverse association between ARA 
levels and fasting insulin (−0.272 per SD; p < 0.001) and 
HOMA-IR (−0.125 per SD; p = 0.03) [33], which is in 
agreement with our findings and points toward a protec-
tive effect between ARA and T2D risk. However, our re-
sults disagree with a recent MR study that reported a 
small but positive causal association between ARA and 
T2D risk (1.03; 95% CI 1.02–1.05; p  =  2.51 × 10−5) with-
in the DIAGRAM consortium [33]. As we both used 
comparable genetic summary statistics for estimating 
ARA levels, this may be an effect of population stratifica-
tion, influenced by small differences in ethnic and geo-
graphic allele frequencies between the UK Biobank (mul-
tiethnic from the UK) and DIAGRAM (white Europeans 
from the UK, Finland, and the USA).
The primary aim of this study was to build on the re-
sults of a 1-sample MR study performed within the EPIC 
cohort 10 years ago [13], predating the introduction of 
2-sample MR [18]. The EPIC population consisted of 
2,653 men and women with genetic data related to SNP 
rs174546 as an instrumental variable of n-6 PUFA syn-
thesis (rather than rs174547 as we have). The r2 between 
rs174546 and rs174547 is 1.0 [34], suggesting perfect link-
age disequilibrium and that MR performed with either 
SNP should provide equivalent estimates. EPIC reported 
a risk ratio of 0.98 with wide confidence intervals (i.e., 
0.70–1.37), suggesting a low power despite the use of a 
strong instrumental variable (i.e., F statistic > 10) [16]. 
This is the strength of 2-sample MR, whereby a robust 
instrumental variable identified in one cohort is applied 
to a second (often larger) cohort with genetic-outcome 
data to improve power. We have taken this approach and 
report that our results fall within the confidence intervals 
of EPIC and now provide a more accurate representation 
of the negligible effect of n-6 PUFA synthesis on T2D risk. 
Recent estimates from the DISCOTWIN consortium 
(n = 34,166 twin pairs) estimate the heritability of T2D to 
be 72% (95% CI 61–78) [35]. Building on this, a GWAS of 
69,142 Icelandic men and women demonstrated that, with-
in a panel of 36 genetic variants associated with blood glu-
cose, more than half were to some degree linked to familial 
heritability of fasting glucose. The FADS1 variant rs174576, 
strongly correlated with rs174547 (r2 = 0.94), was investi-
gated and showed a small but not significant effect (p = 
0.069) on heritability of fasting glucose [36]. As an explor-
atory assessment, we investigated whether the parents and 
siblings of individuals who carry a genetic predisposition 
to lowered n-6 PUFA synthesis are also at an increased risk 
of T2D. Our analysis of parents of siblings suggests that rate 
of n-6 PUFA synthesis is not an important or impactful 
contributor to familial risk of T2D and familial risk is driv-
en by other genetic and environmental factors.
The pathway by which n-6 PUFA affects glucose levels 
and diabetes risk is not well-characterized but it is com-
monly linked to high adiposity and circulating proinflam-
matory eicosanoids. Indeed, circulating levels of n-6 
PUFA have been associated with an increased BMI across 
the lifespan [37, 38] and elevated levels of proinflamma-
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tory eicosanoids in unhealthy and healthy humans [39, 
40]. Recently, two independent MR studies, one using the 
UK Biobank (13,982 T2D cases and 273,412 controls) and 
the other using both the Wellcome Trust Case Control 
Consortium and an Australian adult and adolescent co-
hort (22,669 T2D cases and 58,119 controls) confirmed a 
causative association between an elevated BMI and the 
risk of T2D, i.e., OR = 1.37 (95% CI 1.12–1.68) per kilo-
gram/square meter increase or OR = 1.47 (95% CI 1.17–
1.85) per 5-kg increase [41, 42]. Unfortunately, instru-
mental variables of proinflammatory eicosanoids have not 
been identified that are independent of PUFA levels so the 
causative association of proinflammatory eicosanoids on 
T2D is less well established. Therefore, we sought to inves-
tigate whether the effects of n-6 PUFA levels on T2D were 
driven by the effects of n-6 PUFA on adiposity. Our results 
were not significant and suggest that BMI and n-6 PUFA 
are associated with T2D through independent pathways.
The strength of MR is in its ability to minimize the ef-
fects of confounding; however, as with all studies, we can-
not rule out the possible effects of unmeasured or latent 
confounders. Although our instrumental variable ex-
plained a very high proportion of variation of blood LA 
and ARA levels, we are unable to tease apart or isolate the 
effects of distinct PUFA using instrumental variables. 
However, by accepting this limitation and focusing on 
(1) the causative association of n-6 PUFA synthesis on 
T2D and (2) selecting genetic variants that are more in-
fluential towards n-6 (rather than n-3) PUFA synthesis 
we aimed to minimize this. We also tested our instrumen-
tal variable against the pleiotropic effect of BMI and 
found no association. Perhaps the greatest strength of the 
present study was the very large population, which al-
lowed us to very precisely quantify the very small magni-
tude of effect of n-6 PUFA synthesis on the risk of T2D.
Conclusion
Evidence suggests that any heritable causal association 
between reduced LC n-6 PUFA synthesis and impaired 
glucose metabolism and progression towards T2D that 
does exist in a primarily white European population is 
negligible and likely of little importance in a clinical set-
ting.
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